Pfizer on familiar ground as drug price war re-emerges

3 July 2018

Fairly or not – and perhaps partly to do with the fact that it is simply the biggest and best-known big pharma company – Pfizer (NYSE: PFE) is normally one of the first to get hit when the US media and public hit out at the drug industry over the price of its products.

The US company came bottom of an analysis from the research consulting firm Reputation Institute,  published by Business Insider last month, that rated pharma companies on their reputation.

Considering the general public's perception of product, prices and public hospitality, the study put Pfizer at the bottom, with the report citing its use of a charity to mask a heart drug price hike

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical